Complement Fixation Test: Principle, Procedure, Results, and Types
The Complement Fixation Test (CFT) is a classical, two-stage serological assay that was historically one of the most widely used methods for detecting the presence of either specific antibodies or specific antigens in a patient’s serum. It played a pivotal role in the diagnosis of numerous bacterial, viral, and fungal infections, including syphilis (the Wasserman test), Q fever, and various mycoses, particularly in cases where the causative microbe was difficult to culture. Although it has largely been superseded in modern clinical laboratories by faster, more sensitive, and more standardized methods like ELISA (Enzyme-Linked Immunosorbent Assay) and DNA-based techniques such as PCR (Polymerase Chain Reaction), understanding the CFT’s mechanism provides crucial insight into the fundamental immune processes involving the complement system.
The Fundamental Principle of Complement Fixation
The entire test is predicated on the innate biological property of the complement system—a cascade of serum proteins involved in the innate immune response—to be ‘fixed’ or consumed (bound irreversibly) by certain classes of antibody-antigen (Ag-Ab) complexes. The basic principle revolves around a metabolic competition for complement. The test is structured in two distinct phases: the primary reaction (where the unknown patient sample attempts to fix the complement) and the indicator reaction (which determines if any complement was left unbound).
In the primary reaction, if the patient’s serum contains the specific antibody targeted by the test, a complex forms with the added known antigen. This Ag-Ab complex then binds and consumes (fixes) the measured amount of complement that was introduced into the system. Conversely, if the specific antibody is absent, no Ag-Ab complex forms, and the complement remains free and unbound in the solution. This fixation, or non-fixation, of complement serves as the critical, yet invisible, determinant of the test.
Procedure: The Two-Stage Assay
The Complement Fixation Test procedure is meticulously controlled to ensure that only the reaction between the specific antigen and the patient’s potential antibody determines the outcome. It typically consists of four main steps leading into the two primary reaction stages.
Stage 1: Complement Fixation and Primary Reaction
The initial preparation is to inactivate the patient’s serum, usually by heating it to 56°C for a specific time. This process destroys the patient’s native, biologically labile complement proteins, which are highly susceptible to heat, while leaving the more heat-stable antibodies intact. This inactivation step is essential for standardization, as patients naturally have varying levels of complement. A precisely measured, known amount of standardized complement (often sourced from guinea pig serum) is then added back to the patient’s inactivated serum, along with the specific, known test antigen. The mixture is incubated for a period to allow time for the Ag-Ab complex formation and subsequent complement fixation to occur. If the specific antibody is present, the Ag-Ab complex forms and fixes the complement; if the antibody is absent, the complement remains free.
Stage 2: The Hemolytic Indicator System
The second stage involves adding a pre-prepared Indicator System, known as the hemolytic system (HS). The HS consists of sheep red blood cells (sRBCs) that have been ‘sensitized’ by being pre-coated with an antibody specific to the sRBCs, called hemolysin. The sole purpose of the indicator system is to check for the presence of *free* (unfixed) complement from Stage 1. If any complement remains unbound, it will immediately bind to the sRBC-hemolysin complex and trigger the complement cascade, leading to the lysis (rupture) of the red blood cells, which causes the solution to turn a distinct pink or red color due to the release of hemoglobin.
Interpretation of Results
The final reading of the CFT is based entirely on whether or not hemolysis of the indicator sheep red blood cells has occurred. The results are interpreted in reverse fashion to the reaction being tested:
Positive Test (Specific Antibody Present): No Hemolysis. In a positive result, the solution remains clear, and the intact sRBCs settle as a button at the bottom of the tube. This is a positive result because it signifies that the patient’s antibody reacted with the test antigen in Stage 1, forming an Ag-Ab complex that consumed (fixed) all the available complement. With no free complement left, the indicator sRBCs cannot be lysed in Stage 2. Therefore, no hemolysis equals a positive result for the specific antibody.
Negative Test (Specific Antibody Absent): Hemolysis Occurs. In a negative result, the solution turns pink or red. This indicates that the patient’s serum lacked the specific antibody, so no Ag-Ab complex formed in Stage 1, and the complement was left free. This free complement then reacted with the indicator system in Stage 2, lysing the sRBCs. Therefore, hemolysis equals a negative result for the specific antibody.
Types, Quantification, and Clinical Significance
While the standard procedure described above is a qualitative test used to detect the mere presence or absence of an antibody, the CFT can also be made semi-quantitative. This involves setting up a series of two-fold serial dilutions of the patient’s serum and performing the test on each dilution. The result is reported as a **titer**, which is the highest serum dilution factor that still shows a positive result (i.e., no hemolysis). A higher titer indicates a greater concentration of the specific antibody in the patient’s serum, which is valuable for monitoring the progression or resolution of an infection.
The general principle also allows for variations, such as the **Indirect Complement Fixation Test**, which is sometimes used to detect antibodies to antigens that are already part of a cell structure (like red blood cell antigens). Furthermore, by adapting the initial reagents (adding a known antibody instead of a known antigen), the CFT can be modified to detect and quantify a specific antigen in the patient’s serum.
Clinically, a positive CFT titer, especially a high one or one showing a four-fold increase between acute and convalescent serum samples, often suggests a current or recent infection. This is because IgM antibodies, which are often produced early in an infection, are exceptionally potent complement fixers, requiring only one molecule to initiate the cascade, while IgG antibodies are also fixed, though less efficiently. Despite its historical success and cost-effectiveness, the CFT is less sensitive than ELISA, time-consuming, and prone to issues like “anti-complementary activity” (where components in the serum itself can non-specifically fix complement, leading to false-positive results), which have contributed to its decline in routine diagnostics.